ZP
BDTX icon

Zimmer Partners’s Black Diamond Therapeutics BDTX Stock Holding History

Zimmer Partners’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-17,500
Closed -$437K – 111
2020
Q1 		$437K Buy
+17,500
New +$533K 0.01% 75

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Zimmer Partners's BDTX Position: Q2 2020 in Review

Zimmer Partners sold out of Black Diamond Therapeutics (BDTX) in Q2 2020, closing a stake of 17,500 shares — an estimated $437K sold.

Zimmer Partners first reported a position in BDTX in Q1 2020 and held it in 1 quarter. The position peaked at $437K in Q1 2020. 80 funds tracked by Wall St. Rank hold BDTX as of Q2 2020.

  • Zimmer Partners reported no remaining Black Diamond Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Zimmer Partners sold 17,500 Black Diamond Therapeutics shares in Q2 2020, an estimated $437K.
  • Zimmer Partners first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 1 quarter.
  • Zimmer Partners's Black Diamond Therapeutics position peaked at $437K in Q1 2020.
  • 80 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2020.

Based on Zimmer Partners's 13F filing for Q2 2020, filed 14 Aug 2020.